# What to ask before you pay for PRP *What PRP May Cost — PRP Therapy Mesa* > PRP injection cost and insurance guidance for PRP therapy Mesa readers, with plain questions to ask before paying for care. ## What the price may include Soreness can make a quick answer feel welcome, especially when ordinary tasks are harder. A price quote may arrive before you know what it covers. PRP, or platelet-rich plasma made from the concentrated platelet layer of blood drawn from you, is usually paid by the patient. It’s sensible to ask for the complete cost in writing. The quote may include the visit, the work that separates the blood, the procedure, and later care. It may cover only some of those things. You can ask whether more than one visit is planned. A clear price won’t promise relief, but it can prevent a surprise bill. ## What to ask the clinic and your insurance company Ask the clinic what the total includes and when payment is due. You may also ask whether you owe anything when the exam rules PRP out. Your insurance company can tell you whether the plan pays for any part. Please ask for that answer in writing when possible. Medicare coverage for PRP is narrow and doesn’t generally cover joint or tendon use. Each health plan decides what it will pay. Insurance payment doesn’t prove that a procedure will help your soreness. You’ll still want the clinic to explain why the proposed care fits your body part. ## What to bring before making a choice Take your insurance card, medicines, and any recent joint report. A note about the start of the soreness can keep the visit focused. Ask how many visits are expected and invite the clinic to describe the steps used on your blood. You’re entitled to know what you’re paying for. There’s no single preparation known to suit every sore area. Ask how many platelets the clinic uses, whether the mixture includes white blood cells, and why that choice fits your joint. It’s also fair to ask about exercise, a brace, medicines, or surgery. QC Kinetix can review regenerative options, meaning care without surgery using the concentrated platelet layer from your blood, and explain the proposed costs after examining your joint and health. ## Sources 1. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay. Centers for Medicare & Medicaid Services — [Autologous Platelet-rich Plasma (Coverage with Evidence Development)](https://www.cms.gov/medicare/coverage/evidence/plasma). *CMS.gov*, 2024. 2. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies. Chahla J, Cinque ME, Piuzzi NS, et al. — [A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature](https://pubmed.ncbi.nlm.nih.gov/29040132/). *Journal of Bone and Joint Surgery (American)*, 2017. DOI: 10.2106/JBJS.16.01374. 3. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two. U.S. Food and Drug Administration (Center for Devices and Radiological Health) — [510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=JQC). *FDA accessdata (CDRH device databases)*, 2003. 4. The Cochrane review of STEM CELL injections for knee osteoarthritis concluded that on low-certainty evidence they may slightly improve pain and function, with uncertainty about effects on quality of life, treatment success and structural progression, and uncertainty about safety. This matters on a PRP site because 'stem cell therapy' is routinely used as a marketing label for PRP; they are different products with different evidence and PRP must never be described as a stem cell treatment. Whittle SL, Johnston RV, McDonald S, et al. — [Stem cell injections for osteoarthritis of the knee](https://pubmed.ncbi.nlm.nih.gov/40169165/). *Cochrane Database of Systematic Reviews*, 2025. DOI: 10.1002/14651858.CD013342.pub2. 5. FDA states verbatim of stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming cells from umbilical cord blood, approved only for disorders of blood production, and there are no FDA-approved exosome products. PRP is a different product from all of these and the categories must not be blurred in either direction. U.S. Food and Drug Administration — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA (Center for Biologics Evaluation and Research)*, 2020. 6. In January 2025 the FTC and the Georgia Attorney General obtained federal court orders permanently BANNING the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy, plus $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that the defendants published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic had charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers. Federal Trade Commission — [Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties](https://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51). *FTC Press Release*, 2025. 7. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order. Kolasinski SL, Neogi T, Hochberg MC, et al. — [2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee](https://pubmed.ncbi.nlm.nih.gov/31908163/). *Arthritis & Rheumatology*, 2020. DOI: 10.1002/art.41142. 8. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain. Kon E, de Girolamo L, Laver L, et al. — [Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios](https://pubmed.ncbi.nlm.nih.gov/38961773/). *Knee Surgery, Sports Traumatology, Arthroscopy*, 2024. DOI: 10.1002/ksa.12320. ## What to bring when you’re ready to talk Bring your questions, medicines, and any recent joint report. You won’t need to choose care before someone examines the sore area. QC Kinetix can discuss regenerative treatments, meaning care without surgery using platelet-rich plasma, or PRP, the concentrated platelet layer separated from your blood. Call (602) 837-PAIN for the Chandler or Scottsdale clinic. Talk to the clinic team: --- A comfortable place to start. Plain answers about aching joints in Mesa, simple relief, urgent symptoms, platelet-rich plasma called PRP, costs, coverage, and nearby QC Kinetix care. A plain Mesa guide to aching joints, simple relief, urgent symptoms, and PRP choices. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, who benefit when a reader books with those clinics. Copyright 2026 Mesa PRP Signal. General health education, not medical advice for an individual joint or tendon.